Translocation (12;21), the most frequent chromosomal aberration in childhood acute lymphoblastic leukemia, creates TEL/AML1 fusion gene. Resulting hybrid protein was shown to have a role in pre-leukemia establishment. To address its role for leukemic cell survival, we applied RNA interference to silence TEL/AML1 in leukemic cells. We designed and tested 11 different oligonucleotides targeting the TEL/AML1 fusion site. Using most efficient siRNAs, we achieved an average of 74-86% TEL/AML1 protein knockdown in REH and UOC-B6 leukemic cells, respectively. TEL/AML1 silencing neither decreased cell viability, nor induced apoptosis. On the contrary, it resulted in the modest but significant increase in the S phase fraction and in higher proliferation rate. Opposite effects on cell cycle distribution and proliferation were induced by AML1 silencing, thus, supporting our hypothesis that TEL/AML1 may block AML1-mediated promotion of G1/S progression through the cell cycle. In line with the lack of major effect on phenotype, we found no significant changes in clonogenic potential and global gene expression pattern upon TEL/AML1 depletion. Our data suggest that though TEL/AML1 is important for the (pre)leukemic clone development, it may be dispensable for leukemic cell survival and would not be a suitable target for gene-specific therapy.
Introduction
Wild type (wt) TEL (ETV6) and AML1 (RUNX1) genes encode transcription factors, that have important roles in hematopoiesis, and are frequently re-arranged in human lymphoid and myeloid leukemia. 1, 2 Both genes are affected by the most common genetic abnormality of childhood B-cell precursor acute lymphoblastic leukemia, the cryptic chromosomal translocation t(12;21)(p13;q22), that fuses TEL on chromosome 12 to AML1 on chromosome 21. 3, 4 Resulting TEL/AML1 fusion gene encodes hybrid protein composed of dimerization domain and the central region of TEL fused to almost entire AML1 including the DNA-binding runt homology domain.
Despite intensive studies, the leukemogenic role of TEL/AML1 is not fully understood. In general, TEL/AML1 is believed to interfere with the normal function of its wt counterparts. Most likely, TEL/AML1 acts as an aberrant transcription factor and deregulates AML1-dependent transcription. 5 This theory is strongly supported by the finding that TEL/AML1 in vitro activity is abrogated on loss of DNA binding as a result of a single point mutation within the runt homology domain. 6 As a further evidence, TEL/AML1 was shown to interact with corepressors and histone deacetylases and to repress transcription of AML1 targets through the direct binding to AML1 consensus-binding sites. The promoter regions employed in these reporter assays mainly belonged to the AML1 targets in myeloid 7 or T-lymphoid cells 5, 8, 9 that do not represent the physiological counterparts of TEL/AML1 leukemic cells. Only little is known so far about the direct targets of TEL/AML1 in leukemic cells that are of B-cell origin.
In vivo studies showed that TEL/AML1 is not able to trigger leukemia as a single event and that additional cooperating events are needed for the development of full-blown leukemia. Depending on the experimental model used, presence of TEL/AML1 protein itself either does not lead to any observable changes 10 at all or it induces a 'pre-leukemic' state characterized by the expansion of multipotent or B-cell precursors with enhanced self-renewal and slightly impaired differentiation to more mature B-cell stages. [11] [12] [13] Unlike its role in (pre)leukemic clone origin, the significance of TEL/AML1 protein for leukemia persistence has not been studied enough. To evaluate the contribution of TEL/AML1 to fully malignant phenotype and also to assess the potential of TEL/AML1-targeted therapy, we applied RNA interference (RNAi) to knockdown TEL/AML1 in definitive leukemic cells. RNAi is a complex endogenous mechanism resulting in a sequence-specific gene silencing. It can be triggered by introduction of small interfering RNA molecules (siRNAs), double-stranded RNA oligonucleotides sequentially homologous to the targeted gene. As such, RNAi has a great potential not only for the analysis of gene function but also as a genespecific therapeutic approach.
In our study, we aimed to analyze the impact of TEL/AML1 depletion in the fully malignant leukemic cell on cell viability, proliferation, clonogenic potential and global gene expression pattern. As a study model, we used the only two accessible cell lines established from TEL/AML1-positive patients' leukemias, REH and UOC-B6. Our results indicate that TEL/AML1 fusion gene is not necessary for the survival of leukemic cells and as such would not be a suitable target for specific therapy via RNAi.
Materials and methods

Cell cultivation and transfection
REH (human B-cell precursor leukemia, TEL/AML1-positive) and HELA (human cervix carcinoma) cell lines were purchased from German Collection of Microorganisms and Cell Cultures (DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and cultivated according to producer's instructions. UOC-B6 cell line (human B-cell precursor leukemia, TEL/AML1-positive) 14 was kindly provided by Dr Ondrej Krejci (Massachusetts General Hospital, Boston) and cultivated under the same conditions as REH cell line.
For the transfection experiments, HELA cells were seeded at 160 000 cells per well (2 cm 2 ) 1 day before transfection. Adherent cultures were transfected using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA) reagent according to manufacturer's instructions: 1.6 mg plasmid DNA with 2 ml Lipofectamine or 50 pmol siRNA with 1 ml Lipofectamine in 600 ml serum-free medium per well.
REH and UOC-B6 cells were transfected via electroporation performed on EPI2500 electroporator (Dr L Fischer, Heidelberg, Germany) using 0.4-cm gap Gene Pulser/MicroPulser Cuvettes (Bio-Rad, Hercules, CA, USA) under following conditions: 1 000 000 of cells/100 ml of culture medium, 500 nM siRNA, one pulse of 10 ms, 350 V and 1200 mF. The siRNA transfection efficiency was monitored by flow cytometry.
HELA-TEL/AML1_ires2_enhanced green fluorescent protein (EGFP) permanent cell line
Using restriction endonuclease EcoRI (Fermentas, Burlington, Canada), TEL/AML1 coding sequence was cut from pcDNA3.1 plasmid (kindly provided by Dr Anthony Ford, Institute of Cancer Research, UK) and cloned to pIRES2-EGFP plasmid (BD Bioscience Clontech, Palo Alto, CA, USA). TEL/AML1_ ires2_EGFP plasmid was transfected to HELA cells using Lipofectamine as described above and stable transfectants were selected with geneticin. The stable EGFP expression was verified by flow cytometry, the stable expression of TEL/AML1 protein was analyzed by western blot.
small interfering RNA molecules
In all, 11 TEL/AML1 targeting custom designed siRNAs (TA-1)-(TA-11) (Stealth siRNAs, Invitrogen) were tested for TEL/AML1 knockdown efficiency in HELA-TEL/AML1_ires2_EGFP cells. Non-T1 was used as a negative control (Stealth RNAi siRNA Negative Control Lo GC Duplex 2; Invitrogen). Mix of fluorescein-labeled TA-1 and TA-5 (TA-1 þ 5) was used for TEL/AML1 knockdown in REH and UOC-B6 cells with non-T1 as a negative control.
C1 siRNA used for TEL/AML1 silencing by Diakos et al 15 with set of four siRNAs targeting Tel portion of TEL/AML1 (Tel-set, M-010510-02; Dharmacon, Lafayette, CO, USA) as a positive control and non-T2 (siGENOME non-Targeting siRNA Pool, D-001206-13; Dharmacon) as a negative control was also tested for knockdown efficiency and specificity in REH cells.
AML1 targeting siRNAs pool (AML1-pool, ON-TARGETplus SMARTpool, L-003926-00; Dharmacon) was used for AML1 knockdown in REH cells with non-T3 (ON-TARGETplus nontargeting Pool, D-001810-10; Dharmacon) as a negative control.
All three negative controls (non-T1-3) are designed by producers to have the minimal sequence homology to any known human transcript and have the same chemical structure as the corresponding targeting siRNAs.
RNA isolation and qRT-PCR
Total RNA was extracted using a modification of the method described by Chomczynski and Sacchi 16 or using RNeasy Plus Mini kit (QIAGEN GmbH, Hilden, Germany ) according to the manufacturer's instructions. Total RNA was reverse transcribed into complementary DNA using MoMLV Reverse Transcriptase (Gibco BRL, Carlsbad, TX, USA) according to the manufacturer's instructions.
The TEL/AML1 and b2M transcripts were detected as described previously. 17, 18 The AML1 transcript was amplified using following primers: forward primer (5 0 -GCATATTTGAGTCATTTCCTTCGTAC-3 0 ) and reverse primer (5 0 -CTCGTGCTGGCATCGTGG-3 0 ). qRT-PCR was performed on LightCycler instrument (Roche Diagnostic GmbH, Basel, Switzerland) in a final volume of 20 ml 1 Â QuantiTect SYBR Green PCR Master Mix (QIAGEN) containing 0.8 mmol/l of each primer and 1 ml template cDNA under the following conditions: 94 1C for 15 min; 50 cycles of 94 1C for 5 s, 60 1C for 15 s.
The standard curves were generated using serial dilutions of plasmid calibrators containing the sequences of measured transcripts. The b2M transcript was used as an endogenous control to normalize cDNA concentration and quality.
Protein isolation and western blotting
Nuclear protein lysates were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA) supplemented with Complete Protease Inhibitor Cocktail (Roche) according to manufacturer's instructions. In all, 100 mg of protein was resolved by 8% SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad). Nonspecific binding on the membrane was blocked with phosphate-buffered saline containing 5% dry milk. The membrane was probed with anti-TEL (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-AML1 (Abcam, Cambridge, MA, USA) or anti-LAMIN B (Santa Cruz Biotechnology) antibodies in phosphate-buffered saline containing 5% dry milk overnight. The bound antibody was detected with the appropriate secondary antibody conjugated with horseradish peroxidase and visualized using Immun-Star HRP Substrate Kit (Bio-Rad) followed by exposition to X-ray film.
To quantify proteins detected by western blot, TIFF images of scanned X-ray films were analyzed using ImageJ software. 19 The LAMIN B protein was used an endogenous control to normalize the protein concentration and quality.
Flow cytometry
Flow cytometry was performed on a BD FACSAria Cell Sorting System instrument (Becton Dickinson, San Jose, CA, USA).
Immediately after electroporation of fluorescein-labeled siRNA, transfection efficiency was directly assessed as a percentage of positively fluorescent cells from total transfected cell population.
The intensity of EGFP fluorescence in HELA-TEL/AML1_ ires2_EGFP cells was measured directly after the cell trypsinization and phosphate-buffered saline wash. The acquired data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
DNA content in REH and UOC-B6 cells was measured using Cycletest Plus DNA Reagent Kit (Becton Dickinson) according to manufacturer's instructions. ModFit LT software (Verity Software House, Topsham, ME, USA) was used for data analysis.
To analyze the rate of apoptosis, 100 000 REH and UOC-B6 cells were washed in phosphate-buffered saline, re-suspended in 50 ml of Annexin-V-binding buffer and stained on ice with 2.5 ml of propidium iodide and 2.5 ml of Dy647-conjugated Annexin-V in dark. After 30 min, cells were washed with Annexin-Vbinding buffer, re-suspended in 100 ml of Annexin-V-binding
buffer and analyzed by flow cytometry. The acquired data were analyzed using FlowJo software. Proliferation rate was assessed as DNA synthesis rate in REH cells measured using Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Invitrogen) according to manufacturer's protocol. Cells were pulsed with EdU for 12 h and subsequently analyzed. As a part of the manufacturer's protocol, DNA content was measured by Click-iT EdU Cell Cycle 488-red dye (Invitrogen). The acquired data were analyzed using FlowJo software.
Mann-Whitney test was used for statistical analysis of cytometric data.
Gene expression analysis
Spotted cDNA microarrays were used that contain more than 43 000 features representing about 30 000 genes (Stanford Functional Genomics Facility, Stanford, CA, USA). The reference RNA used for all the arrays was Universal Human Reference RNA (Stratagene Europe, Amsterdam, The Netherlands). We labeled each of the sample with a red fluorescent dye (Cy5-dUTP, Amersham Pharmacia Biotech Europe, Freiburg, Germany) and the reference RNA with a green fluorescent dye (Cy3-dUTP, Amersham Pharmacia Biotech Europe) and comparatively hybridized sample RNA and reference RNA to an array. Each experiment was done in triplicates. The fluorescence intensities of Cy5 and Cy3 were measured using a GenePix 4000 scanner (Axon Instruments, Foster City, CA, USA) and analyzed using GenePix Pro 4.1 software (Axon Instruments). Subsequent analysis and normalization of data was done as previously described (Cario et al., Blood 2005) . To analyze the data in a supervised approach, we used significance analysis of microarrays (SAM) with a 1000-fold permutation and considering a false discovery rate of 5% as significant. 20 
Clonogenic cell assays
The colony-forming capacity was analyzed using Human Methylcellulose Base Media (R&D Systems, Minneapolis, MN, USA) according to manufacturer's instruction. Three cultures per each sample of experimental triplicate were set up in 35-mM culture dishes (STEMCELL Technologies, Vancouver, Canada) 4 h after the second round of siRNA transfection (TP 52 h). Colonies were counted after 10 days of incubation using 60-mm gridded scoring dish (STEMCELL Technologies) and an inverted microscope.
Limiting-dilution cultures were set up at TP 52 h. In all, 12 aliquots per each sample of experimental triplicate diluted to limiting concentration (5 cells/100 ml ) were cultivated in roundbottomed wells of a 96-well plate (100 ml of culture medium per well) under the standard conditions. The growth of clones was scored after 10 days of incubation in an 'all-or-nothing' fashion using an inverted microscope.
Mann-Whitney test was used for statistical analysis of clonogenic cell assays.
Results
Identification of the efficient and specific siRNAs targeting the TEL/AML1 fusion
We designed 11 different Stealth siRNAs (TA-1)-(TA-11) targeting the transcriptomic TEL/AML1 fusion site. The Stealth siRNAs synthesized by Invitrogen are 25 nucleotides long blunt-ended duplexes that are chemically modified in order to minimize the off-target effects associated with induction of cellular stress response and sense strand guided silencing. Our siRNAs were designed with target sites moved by one nucleotide each, all of them spanning the fusion point and, thus, lacking the total sequence homology to wt TEL and AML1 genes to avoid their silencing ( Figure 1 ). Our siRNAs also do not have sequence homology to any other known human transcript further diminishing the potential risk of the off-target silencing.
To effectively test the efficiency of siRNAs, we employed the HELA-TEL/AML1_ires2_EGFP model. HELA-TEL/AML1_ires2_ EGFP cells are permanently transfected with TEL/AML1_ ires2_EGFP construct and express a single bicistronic mRNA from which both TEL/AML1 fusion protein and EGFP are translated. siRNA targeting the TEL/AML1 fusion region of the bicistronic mRNA triggers silencing of both TEL/AML1 and EGFP and, thus, we could highly accurately and reproducibly compare the efficiency of our siRNAs by measuring decrease of EGFP fluorescence by flow cytometry. The efficiency of individual siRNAs assessed 48 h after siRNA transfection varied from 58 to 6% (that is, EGFP fluorescence was reduced to 42-94% of its level in control, Figure 2a) .
The five most efficient siRNAs (TA-1)-(TA-5), that induced the reduction of EGFP fluorescence to at least 50% of its level in control, were further tested in TEL/AML1-positive leukemic REH cells. Electroporation by rectangular pulses was used to deliver siRNAs into REH cells. Transfection efficiency monitored as incorporation of fluorescein-labeled siRNAs by flow cytometry reached 90% and more. We compared the TEL/AML1 knockdown efficiency of individual tested siRNAs at the mRNA level 24 h after transfection (analysis of time points 12, 24 and 48 h after transfection revealed that at the transcript level silencing reaches its maximum 24 h after transfection). We found the siRNAs TA-1 and TA-5 to be the most efficient ones inducing in average 58 and 57% transcript knockdown, respectively (Figure 2b) .
We pooled fluorescein-labeled TA-1 and TA-5 (TA-1 þ 5) siRNAs and further compared their efficiency with C1 siRNA used for TEL/AML1 silencing by Diakos et al. 15 Commercially available set of four siRNAs (TEL-set) with validated efficiency targeting the TEL portion of TEL/AML1 was used as a positive control. The efficiency of TA-1 þ 5 in REH cells was comparable to TEL-set (61 and 64% knockdown, respectively) and higher than the efficiency of C1 siRNA (48% knockdown) (Figure 2c ). Although our siRNAs were designed to be strictly TEL/AML1 specific, we wanted to directly prove that they do not influence the level of wt allele transcripts. Like in the majority of TEL/AML1-positive acute lymphoblastic leukemias, the wt TEL is deleted in both cell lines used in this study and, thus, the potential risk of its silencing is abolished. However, this is not the case of wt AML1. We analyzed the AML1 transcript level 24 h after siRNA transfection and found that C1 siRNA caused 46% AML1 knockdown while our TA-1 þ 5 siRNA pool caused only a negligible reduction (14%) of AML1 transcript level (Figure 2d ). Thus, we found our TA-1 þ 5 siRNAs pool to be more efficient and far more specific than previously published C1 RNAi oligo.
TEL/AML1 knockdown in REH and UOC-B6 cells
Having identified the most efficient and specific siRNAs, we analyzed their potential to silence TEL/AML1 protein. We found no effect at the protein level after the single siRNA transfection into REH cells at the time points 24, 48 and 72 h and only a slight reduction of TEL/AML1 protein 96 h after transfection (data not shown). This potentially indicates a longer half-life of TEL/AML1 protein, so to achieve its knockdown we had to further optimize the experimental design to prolong and maximize the transcript silencing. Finally, we performed two rounds of siRNA transfection in 48-h interval with the evaluation of transfection efficiency and transcript reduction after each transfection and the protein analysis 48 h after the second transfection (time point 96 h, see Figure 3 ). Using this scheme, we reached a substantial depletion of TEL/AML1 protein in REH cells in all three experimental replicates: 68, 73 and 81% knockdown, respectively (Figure 4a ). Using the identical approach, similar results were also obtained in another TEL/AML1-positive leukemia cell line, UOC-B6: 75, 89 and 93% TEL/AML1 protein knockdown, respectively (Figure 4b ). In both cell lines, TEL/AML1 depletion was still detectable 24 h later (time point 120 h).
The biological consequences of TEL/AML1 knockdown in REH and UOC-B6 cells
Next, we studied the impact of TEL/AML1 knockdown on cell viability and cell cycle distribution. We performed several . Utilizing trypan blue staining followed by optical microscopy, we did not observe any decrease in viability of TEL/AML1-depleted cells. In agreement with this observation, we did not detect the increased apoptosis rate assessed by annexin V and propidium iodide staining. We further analyzed the cell cycle distribution by measuring the DNA content using flow cytometry. In any of the time points studied, we found neither changes in subG1 fraction indicative of apoptosis nor G1/G0 cell cycle arrest. We observed modest but reproducible changes of the cell cycle distribution after reaching maximum TEL/AML1 depletion in both REH and UOC-B6 cell lines used in this study (time point 120 h; Figure 6a ): The fraction of S phase cells increased (from 24.5 to 28.8% in REH and from 28.4 to 34.1% in UOC-B6; P ¼ 0.0495) with a corresponding decrease in the fraction of G0/G1 phase cells within TA-1 þ 5-treated population compared with controls (from 68.0 to 64.1% in REH and from 66.5 to 59.8% in UOC-B). To address the question whether the observed increase in S phase is accompanied by the higher proliferation rate, we pulsed the TEL/AML1-depleted REH cells with EdU nucleoside analog. After 12-hpulse, we measured the percentage of cells that incorporated EdU, and, thus, entered or passed the S phase of the cell cycle. On TA1 þ 5 siRNA treatment, more cells incorporated EdU compared with control siRNA-treated cells (63.7 vs 61.0%, P ¼ 0.0495; Table 1 ) giving evidence of higher proliferation rate. The proportion of cells in S and G2M phases within the total EdU-positive population measured by DNA staining did not differ between TA1 þ 5 and control-treated cells, thus, indicating a normal passage through the S phase in TEL/AML1-depleted cells (Supplementary Figure 1) .
To study the impact of TEL/AML1 silencing on the clonogenic potential of leukemic cells, we analyzed their colony-forming capacity and clonal growth in limiting-dilution cultures. We found that only REH cell line, but not UOC-B6 cell line, forms colonies in semi-solid methylcellulose-based medium. The colony-forming capacity (number of colonies, size and shape of colonies) of REH cells with silenced TEL/AML1 did not significantly differ from the controls (Supplementary Figure 2A) . In agreement with this finding, we found no changes of clonal growth frequency in limiting-dilution cultures of both REH and UOC-B6 cells with silenced TEL/AML1 (Supplementary Figure 2B and C).
To assess the impact of TEL/AML1 on the global gene expression pattern we performed genome-wide gene expression profiling of REH cells 24 h after TEL/AML1 protein depletion (time point 120 h). No significantly differentially expressed genes were identified comparing treated and untreated cells (SAM, 1000 permutations, false discovery rate o5%).
The biological consequences of AML1 knockdown in REH cells
It was previously demonstrated that AML1 promotes the transition from the G1 to the S phase of cell cycle. 21, 22 We hypothesized that TEL/AML1, at least partially, interferes with this process and that the cell cycle changes found after TEL/AML1 depletion resulted from the restoration of AML1 The fraction of de novo DNA synthesizing cells was assessed by flow cytometry as a percentage of the cells that incorporated nucleoside analog EdU (EdU-positive) from the total EdU-pulsed population; s.d. of triplicate of experiment.
TEL/AML1 silencing M Zaliova et al function. Therefore, we performed an opposite experiment, we silenced AML1 and analyzed the effect of this on the cell cycle. As the TEL/AML1 fusion includes almost entire AML1, the commercially available validated siRNA pool (AML1-pool) used for AML1 knockdown targets both wt AML1 and TEL/AML1. We used the same experimental scheme with double transfection as described above and we achieved an excellent suppression of AML1 protein in REH cells in all three experimental replicates: 91, 92 and 94%, respectively ( Figure 5 ). The concomitant suppression of TEL/AML1 protein by AML1-pool reached 30, 59 and 73%, respectively. In agreement with our hypothesis, AML1 depletion had an opposite effect on REH cell cycle distribution compared with TEL/AML1 depletion. With the maximum intensity 48 h after depletion the fraction of S phase cells significantly decreased (from 26.0 to 22.1%; P ¼ 0.0495) while the fraction of G0/G1 phase cells significantly increased in AML1-pool-treated cells (from 63.5 to 68.7%; P ¼ 0.0495; Figure 6b ). In line with the changes of cell cycle distribution, EdU pulse-chase experiments demonstrated a reduction of proliferation rate on AML1 silencing (50.4 vs 55.5%, P ¼ 0.0495; Table 1 ).
Discussion
In our study, we tested the effect of TEL/AML1 knockdown in human leukemic TEL/AML1-positive cells. Knowing that highly efficient and specific siRNA would be the key step to perform successful RNAi, we designed a set of all possible Stealth siRNA's (n ¼ 11) specifically targeting the TEL/AML1 fusion region without targeting the wt TEL and AML1. We used an EGFP-reporter system in HeLa cells to check their efficiency and after an arduous process of optimizing the transfection, we subsequently tested selected siRNAs in human TEL/AML1-positive cell line. The two most efficient siRNAs were than pooled for further experiments. We reached adequate TEL/AML1 silencing on both mRNA and protein level reproducible in two TEL/AML1-positive cell lines.
One would expect that silencing of TEL/AML1, a fusion protein which is the hallmark of nearly one-fourth of all childhood B-cell precursor leukemias, leads to major changes in the cell survival, cell cycle and/or expression profile of the target genes. Such an effect was described for other chimearic genes in leukemias, including BCR/ABL and MLL/AF4. [23] [24] [25] However, in our experiments, we observed rather subtle changes in the cell cycle and neither changes in survival and self-renewal characteristics of TEL/AML1-positive leukemic cell lines nor changes in the gene expression pattern. Nevertheless, we are convinced that our results are in line with the current knowledge of the natural history of childhood acute lymphoblastic leukemia carrying TEL/AML1 fusion. TEL/AML1 fusion is known to originate during the prenatal period of life. [26] [27] [28] This single genetic aberration leads to the generation of an covert pre-leukemic clone (found in up to 1% of normal physiological newborns) with a low probability of conversion to a definitive full-blown leukemia. This process requires further genetic events and takes typically 2-6 years, given the age distribution of TEL/AML1-positive acute lymphoblastic leukemia. 29 In accord with these epidemiological data, in vitro and in vivo experiments confirm the insufficiency of TEL/AML1 fusion alone for the malignant transformation. In some of the murine models, TEL/AML1 transduction did not lead to any phenotypic changes; 10 in others to the increase of multipotent or B-cell progenitors numbers with an incomplete differentiation block. [11] [12] [13] In none of these models, TEL/AML1 expression had led to the leukemia origin without other TEL/AML1 silencing M Zaliova et al additional genetic changes. Genomic profiling showed that TEL/ AML1-positive leukemic blasts carry in average 6.7 additional copy-number alterations. 30 Most recent twin study by Bateman et al. documents that these secondary ('second-hit') changes affect both genes regulating differentiation and proliferation (PAX5, EBF1, CDKN2A/B and RB1 deletions) suggesting both these processes may be deregulated in leukemic cells independently of TEL/AML1. 31 In addition, we demonstrated that aberrant expression of specific miRNAs in TEL/AML1-positive blasts provides survival advantage to growth inhibitory signals and represents another event independent of TEL/AML1. 32 Recent work of Schindler et al. demonstrated that only TEL/AML1 expression in HSC's has the potential for leukemia initiation in contrast to TEL/AML1-expressing committed lymphoid progenitors. 33 They also showed that TEL/AML1-positive hematopoietic stem cells (HSC's) did not progressively accumulate over time, did not outcompete the wt HSC's, were more quiescent than wt HSC's and did not exhibit deregulated expression of major known regulators of HSC's. Thus, when translating this knowledge to the clinical setting, TEL/AML1-positive HSC's can survive in the patient's organism for a long period of time waiting for the secondary event or the series of them. One potential mechanism for the long-term survival and propagation of the pre-leukemic clone was proposed by Ford et al. In the reaction to TGFB signaling, TEL/AML1-positive pre-leukemic cells can exert their proliferative advantage and expand. 34 Ford et al. also analyzed the cell cycle changes after induced expression of TEL/AML1 in the murine BaF3 cell line. They clearly demonstrated that TEL/AML1-expressing cells elevated the G0/G1 fraction, decreased S/G2/M fraction and slowed down the proliferation. This is in agreement with the subtle, but significant, opposite changes in the cell cycle observed in our experiments after TEL/AML1 silencing. We also show that REH cells with TEL/AML1 knockdown tend to have higher proliferation rate. It was previously demonstrated that AML1 stimulates G1 to S progression and shortens the G1 phase of the cell cycle. 21, 22 This function of AML1 seems to be inhibited by AML1/ETO fusion protein. 35 We hypothesized that TEL/AML1 also partially inhibits AML1 function and that the observed cell cycle changes occurred because of the functional restoration of AML1 after TEL/AML1 depletion. To prove this hypothesis, we performed the opposite experimentFRNAi-mediated AML1 knockdownFand analyzed the cell cycle and proliferation. AML1 silencing indeed led to the increase in G1/G0 phase and decrease in S phase and to slowing the overall proliferation rate. This shows that the functional block of AML1 by TEL/AML1 is incomplete and, thus, we observe enhancement of the changes typical for TEL/AML1 presence when AML1 is totally depleted.
One of the obvious effects of silencing a potential leukemogenic fusion gene to be tested would be the changes in the expression profile. The pattern of changes may point to the functional pathways to be disrupted and help to identify the target genes of the culprit. So far, no direct target gene of AML1 and/or TEL/AML1 proteins was identified and only handful were proposed in the lymphoid lineage. 36, 37 We have previously published the list of potential TEL/AML1-regulated genes, identified among upregulated genes in the expression profile of REH cells treated with HDACi (thus, targeting the functional pathway of TEL/AML1 protein function). 8 Given the subtle effect of TEL/AML1 silencing on cell cycle and survival, we did not expect major changes in gene expression profiling performed 24 h after RNAi-mediated TEL/AML1 silencing. Indeed, no detectable changes were recorded by gene expression profiling analysis. This finding, though seemingly counterintuitive is, in fact, in agreement with the findings of Fischer et al, who also found very subtle changes in the gene expression profiling of TEL/AML1-transduced HSC's. 11 Clearly, the potential of RNAi in the search for potential target genes of the 'first hit' aberrations in leukemia is rather limited.
During our work on the current project, contradictory data on TEL/AML1 silencing were published. 15 It was described that TEL/AML1 silencing has an proapoptotic effect and leads to profound changes in gene expression profiles. However, we found that the siRNA oligo used in that study (C1) is not exclusively specific for the TEL/AML1 fusion but is fully complementary to the wt AML1 sequence (see Figure 1 for sequence comparison). This different silencing pattern mightF at least in partFexplain the differences between our data and these data. Our experiments confirmed that AML1 was efficiently silenced using the oligo C1, however, the TEL/AML1-targeted efficacy was lower than the combination of oligos we designed and used in the current study (TA-1 þ 5). Therefore, the lack of apoptosis we observed using our TA-1 þ 5 oligos clearly cannot be caused by the insufficient knockdown. This notion is further supported by the fact that more efficient silencing in UOC-B6 cell line (average of 86 vs 74% in REH) resulted in more profound changes in the cell cycle (S phase increase: 5.7% in UOC-B6 vs 4.3% in REH; G1 decrease: 6.7% in UOC-B6 vs 3.9% in REH). Additional increase of the silencing efficacy would very likely intensify these changes, but would not lead to a reverse effect. Interestingly, in contrast to other studies working with the identical model cell system, Diakos and colleagues showed that the ectopic expression of TEL/AML1 leads to the growth factor independence in BaF3 cell. 10, 34 Here, further models are needed to find the real effect of an TEL/AML1 ectopic expression.
The primary conclusion of our study is that TEL/AML1 silencing neither induces cell cycle arrest/apoptosis nor attenuates clonogenic potential in the studied TEL/AML1-positive cell lines. Further studies will be needed to address the question whether TEL/AML1 silencing has some specific effect on 'leukemia-initiating cells' and whether it affects self-renewal and leukemia persistence in vivo. In this report, we show that TEL/AML1 silencing did not affect the viability of leukemic cell lines suggesting that it may be dispensable for the survival of definitive leukemic cells.
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